Grifols (GIFLF) Other Accumulated Expenses (2009 - 2025)
Grifols' (GIFLF) quarterly Other Accumulated Expenses came in at $642.6 million in Q4 2025, down 11.05% on a YoY basis from $722.4 million in Q4 2024, and down 11.05% quarter-over-quarter from $722.4 million in Q4 2024.
Analysis
Grifols (GIFLF) Other Accumulated Expenses (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Other Accumulated Expenses for 17 consecutive years, with $642.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses fell 11.05% year-over-year to $642.6 million; the trailing twelve-month figure through Dec 2025 stood at $642.6 million (down 11.05% YoY), and the FY2025 full-year result was $623.7 million, down 13.67% from the prior year.
- Other Accumulated Expenses declined to $642.6 million in Q4 2025 per GIFLF's latest filing, from $722.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.1 billion in Q4 2023 and bottomed at $250.8 million in Q4 2021.
- Historically, Other Accumulated Expenses has averaged $706.9 million across 5 years, with a median of $722.4 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses soared 225.77% in 2022, then sank 34.41% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $250.8 million in 2021, then jumped by 225.77% to $817.2 million in 2022, then jumped by 34.78% to $1.1 billion in 2023, then tumbled by 34.41% to $722.4 million in 2024, then fell by 11.05% to $642.6 million in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $642.6 million, $722.4 million, and $1.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 642.55 Mn |
| Dec 31, 2024 | 722.37 Mn |
| Dec 31, 2023 | 1.10 Bn |
| Dec 31, 2022 | 817.16 Mn |
| Dec 31, 2021 | 250.84 Mn |
| Dec 31, 2020 | 182.61 Mn |
| Sep 30, 2020 | 1.08 Bn |
| Mar 31, 2020 | 1.11 Bn |
| Dec 31, 2019 | 218.50 Mn |
| Sep 30, 2019 | 1.09 Bn |
| Dec 31, 2018 | 193.11 Mn |
| Sep 30, 2018 | 975.69 Mn |
| Jun 30, 2018 | 165.40 Mn |
| Mar 31, 2018 | 1.09 Bn |
| Dec 31, 2017 | 170.02 Mn |
| Jun 30, 2017 | 141.55 Mn |
| Dec 31, 2016 | 151.36 Mn |
| Sep 30, 2016 | 133.26 Mn |
| Jun 30, 2016 | 125.37 Mn |
| Dec 31, 2015 | 147.61 Mn |